India, Aug. 15 -- Eli Lilly and Company (India) has announced thatMounjaro(R)KwikPen(R)(tirzepatide)is now available across India in all doses.

Approved by theCentral Drugs Standard Control Organisation (CDSCO), Mounjaro(R)KwikPen(R), a prescription-based, once-weekly treatment, offers a convenient way for patients to administer their medication.

Mounjaro(R)is the first and only dual agonist ofglucose-dependent insulinotropic polypeptide (GIP)andglucagon-like peptide-1 (GLP-1)receptors, indicated as an adjunct to diet and exercise for the treatment of:

Mounjaro(R)KwikPen(R)is a multi-dose, single-patient-use prefilled pen. Each pen contains four fixed doses, administered once weekly. The pen will be available in six dose strengths: 2.5...